Umihanic Sefika, Novakovic Lora, Alidzanovic Lejla, Kuduzovic Medina Bandovic, Sehic Anida, Muhic Almedina, Kovcic Amila, Selak Nejra
Clinic for Oncology and Radiotherapy, University Clinical Center Tuzla, 75000 Tuzla, Bosnia and Herzegovina.
Clinic for Pulmology, University Clinical Center Banja Luka, 78000 Banja Luka, Bosnia and Herzegovina.
J Clin Med. 2025 Mar 25;14(7):2219. doi: 10.3390/jcm14072219.
Squamous cell lung cancer (SCC) presents a significant treatment challenge due to its poor prognosis and limited therapeutic options. In many resource-limited countries, access to advanced molecular testing is often unavailable, making the identification of novel and reliable prognostic markers crucial for improving patient selection for systemic treatments. This single-center, retrospective study investigated the prognostic value of inflammatory biomarkers, including the systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR), in 134 patients diagnosed with SCC. Patients were stratified into groups based on optimal cut-off values determined by ROC analysis for each biomarker. Elevated levels of the SII, NLR, and PLR were significantly associated with shorter overall survival in patients with SCC (all < 0.05). These easily accessible and cost-effective laboratory parameters are particularly valuable in settings where molecular testing is not available, aiding in the identification of high-risk patients and optimizing treatment selection for chemotherapy.
肺鳞状细胞癌（SCC）因其预后不良和治疗选择有限而带来重大的治疗挑战。在许多资源有限的国家，往往无法进行先进的分子检测，因此确定新的可靠预后标志物对于改善全身治疗的患者选择至关重要。这项单中心回顾性研究调查了134例确诊为SCC的患者中炎症生物标志物的预后价值，包括全身免疫炎症指数（SII）、中性粒细胞与淋巴细胞比值（NLR）和血小板与淋巴细胞比值（PLR）。根据每个生物标志物通过ROC分析确定的最佳临界值将患者分层。SII、NLR和PLR水平升高与SCC患者的总生存期缩短显著相关（均P<0.05）。这些易于获取且具有成本效益的实验室参数在无法进行分子检测的情况下尤其有价值，有助于识别高危患者并优化化疗的治疗选择。
